According to a report of a single centre’s experience using the Medina embolisation device (Medtronic) for the treatment of unruptured aneurysms, the device “represents a major step forward” in the treatment of intracranial aneurysms.
UCLA researchers have shown that the brain can be repaired—and brain function can be recovered—after a stroke in animals. The discovery could have important implications for treating a mind-robbing condition known as a white matter stroke, a major cause of dementia.
Codman Neuro has announced the acquisition of Pulsar Vascular Inc, a privately-held company with breakthrough platform technology for the neurovascular treatment of complex aneurysms. DePuy Synthes Products Inc, an affiliate of Codman Neuro, is the acquiring entity.
Comparing the outcomes on computed tomography (CT) perfusion of patients with large baseline ischaemic cores undergoing endovascular therapy with the outcomes of matched controls who had medical care alone, Leticia C Rebello and colleagues from the Grady Memorial Hospital, Emory University School of Medicine, Atlanta, USA, found that, in properly selected patients, endovascular therapy appears to benefit patients with large core and large mismatch profiles.
Investigators using the p64 Flow Modulation Device (Phenox) for the treatment of unruptured intracranial aneurysms at six centres have revealed that mid- and long-term follow-up show that endovascular treatment with the p64 Flow Modulation Device is a safe treatment for unruptured cerebral aneurysms, resulting in a high rate of occlusion.
The US Food and Drug Administration (FDA) has cleared an expanded indication for the Solitaire stent retriever device (Medtronic). The FDA now allows the marketing of the Solitaire device as an initial therapy for acute ischaemic strokes for patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts to reduce paralysis, speech difficulties and other stroke-related disabilities. The device should be used after patients have received intravenous tissue plasminogen activator (IV t-PA) and within six hours of symptom onset.
Neuravi has announced €15 million in venture debt financing from IPF Partners, a leading alternative financing provider focused on the healthcare sector.
A higher neighbourhood advantage, or socioeconomic status, of where a person lives contributes to a lower risk of having a stroke no matter the person’s race, according to findings published in an online issue of Neurology, the medical journal of the American Academy of Neurology.
Stroke patients are starting a trial of a new electronic device to recover movement and control of their hand. Neuroscientists at Newcastle University, UK, have developed the device, the size of a mobile phone, which delivers a series of small electrical shocks followed by an audible click to strengthen brain and spinal connections.
Researchers have developed a first-of-its-kind tool to help predict a person’s chance of survival after a gunshot wound in the head or other penetrating injury, according to a new study published in a recent online issue of Neurology. The tool is called the SPIN-Score, which stands for Surviving Penetrating Injury to the Brain.
In the ANSWER (Adjunctive neurovascular support of wide-neck aneurysm embolization and reconstruction) study of the PulseRider device (Pulsar Vascular), enrolment, 30-day and 180-day follow-up are complete for all 34 patients. At the moment, 365-day follow-up on eight patients is complete, and investigators are in the process of collecting these data on the remaining patients; which should be complete by the end of the year. Now, NeuroNews speaks to principal investigator Alejandro Spiotta (Medical University of South Carolina, USA) about his experience.
Medtronic has announced that it has notified customers of a voluntary recall of certain lots of its Pipeline embolization device, Alligator retrieval device and X-Celerator hydrophilic guidewire. The recall also includes the stylet containing UltraFlow flow directed micro catheters and Marathon flow directed micro catheters. These products are produced, marketed and sold by Medtronic’s Neurovascular business, which is part of the Brain Therapies division in the company’s Restorative Therapies Group.
A new study comparing acute damage to the arterial wall caused by ADAPT (a direct aspiration first pass technique) or stent retrievers during thrombectomy procedures has found that while both techniques caused acute damage to the vessel walls, thrombectomy with a stent retriever appeared to be more harmful to all layers of the arterial wall, particularly the endothelium.
Now that mechanical thrombectomy for the treatment of acute ischaemic stroke is on its way to becoming well-established practice, new devices are beginning to emerge. One such device is a new clot retriever technology—Ncap device from NOHA—which has thus far been tested in animal models.
There is no doubt now that mechanical thrombectomy has been established as the new standard of care for the treatment of emergent large vessel occlusion stroke. But moving forward, stroke teams around the world have begun to look for ways in which the process can be improved so that the treatment can reach as many patients as possible, as quickly as possible. To do this, increasing focus is being placed on improving the pathways of care.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos